Advancements in the Management of Heart Failure with Reduced Ejection Fraction (HFrEF): Current Strategies and Future Directions
DOI:
https://doi.org/10.48047/Keywords:
Keywords: Heart failure with reduced ejection fraction (HFrEF), Guideline-directed medical therapy (GDMT), ACE inhibitors, SGLT2 inhibitors, Future directions in HFrEF.Abstract
Heart failure with reduced ejection fraction (HFrEF) remains a major clinical challenge, with evolving management strategies aimed at improving patient outcomes. This article provides a comprehensive overview of current treatment protocols for HFrEF, including the role of guideline-directed medical therapy (GDMT), multidisciplinary care teams, and emerging therapies. It outlines the core pharmacological agents recommended in recent guidelines, such as ACE inhibitors/ARNI, beta-blockers, mineralocorticoid receptor
antagonists (MRAs), and SGLT2 inhibitors, highlighting their pivotal role in optimizing treatment. The article also addresses the importance of early initiation of these therapies and the need for a personalized, patientcentered approach
